Oxford Immunotec Global PLC (OXFD) Earning Somewhat Positive Media Coverage, Analysis Shows
Press coverage about Oxford Immunotec Global PLC (NASDAQ:OXFD) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global PLC earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.0964168891807 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference (finance.yahoo.com)
- Oxford Immunotec Global PLC (OXFD) Lowered to “Sell” at Zacks Investment Research (americanbankingnews.com)
- -$0.25 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter (americanbankingnews.com)
- Oxford Immunotec Global PLC (OXFD) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
Several equities analysts have recently commented on OXFD shares. Cowen and Company restated a “buy” rating and issued a $22.00 price objective on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. BTIG Research restated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price objective on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.25.
Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) traded up 2.06% during midday trading on Thursday, reaching $15.82. 209,938 shares of the company traded hands. The stock’s market capitalization is $365.06 million. Oxford Immunotec Global PLC has a 12 month low of $9.49 and a 12 month high of $19.51. The company’s 50 day moving average is $16.55 and its 200-day moving average is $15.27.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). The company had revenue of $26.10 million during the quarter, compared to analysts’ expectations of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The business’s quarterly revenue was up 35.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. Equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.63) earnings per share for the current fiscal year.
In related news, VP Elizabeth M. Keiley sold 4,085 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $15.01, for a total transaction of $61,315.85. Following the sale, the vice president now owns 25,393 shares in the company, valued at approximately $381,148.93. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the company’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $16.06, for a total value of $481,800.00. Following the sale, the chief executive officer now owns 491,668 shares in the company, valued at approximately $7,896,188.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 126,195 shares of company stock worth $2,073,682. 7.58% of the stock is owned by corporate insiders.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.